{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T08:19:42Z","timestamp":1710577182112},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11936-001-0096-4","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T14:55:48Z","timestamp":1181228148000},"page":"347-357","source":"Crossref","is-referenced-by-count":2,"title":["Dyslipidemia"],"prefix":"10.1007","volume":"3","author":[{"given":"Adam M.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"96_CR1","doi-asserted-by":"publisher","first-page":"3U","DOI":"10.1016\/S0002-9149(98)00957-6","volume":"82","author":"PO Kwiterovich","year":"1998","unstructured":"Kwiterovich PO Jr: State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol 1998, 82:3U-17U. A comprehensive review of the studies that have demonstrated the epidemiologic, angiographic, and clinical association between lipid-lowering and CAD. It includes data from several classes of hypolipidemic agents and addresses both primary and secondary prevention.","journal-title":"Am J Cardiol"},{"key":"96_CR2","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486\u20132497.","journal-title":"JAMA"},{"key":"96_CR3","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1016\/S0002-9149(98)00806-6","volume":"82","author":"TA Pearson","year":"1998","unstructured":"Pearson TA: Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am J Cardiol 1998, 82:28S-30S.","journal-title":"Am J Cardiol"},{"key":"96_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-133-7-200010030-00015","volume":"133","author":"TA Jacobson","year":"2000","unstructured":"Jacobson TA: \u201cThe lower the better\u201d in hypercholesterolemia therapy: a reliable clinical guideline?\n                           Ann Intern Med 2000, 133:549\u2013554.","journal-title":"Ann Intern Med"},{"key":"96_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archinte.160.4.459","volume":"160","author":"TA Pearson","year":"2000","unstructured":"Pearson TA, Laurora I, Chu H, et al.: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459\u20134567. This study demonstrates the gap that exists between establishing guidelines and achieving them.","journal-title":"Arch Intern Med"},{"key":"96_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","volume":"279","author":"RS Rosenson","year":"1998","unstructured":"Rosenson RS, Tangney CC: Antiatherogenic properties of statins. JAMA 1998, 279:1643\u20131650.","journal-title":"JAMA"},{"key":"96_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2165\/00003495-199856040-00001","volume":"56","author":"DC Wheeler","year":"1998","unstructured":"Wheeler DC: Are there potential non-lipid-lowering uses of statins?\n                           Drugs 1998, 56:517\u2013522.","journal-title":"Drugs"},{"key":"96_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213\u2013219.","journal-title":"J Cardiovasc Risk"},{"key":"96_CR9","first-page":"21","volume":"22","author":"The BIP Study Group","year":"2000","unstructured":"The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 22:21\u201327.","journal-title":"Circulation"},{"key":"96_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1056\/NEJM199511163332002","volume":"333","author":"TA Miettinen","year":"1995","unstructured":"Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308\u20131312.","journal-title":"N Engl J Med"},{"key":"96_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0002-9149(00)00976-0","volume":"86","author":"SN Blair","year":"2000","unstructured":"Blair SN, Capuzzi DM, Gottlieb SO, et al.: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000, 86:46\u201352.","journal-title":"Am J Cardiol"},{"key":"96_CR12","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/01.CIR.102.20.2555","volume":"102","author":"JW Erdman","year":"2000","unstructured":"Erdman JW, for the AHA Nutrition Committee: Soy protein and cardiovascular disease. A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000, 102:2555\u20132519.","journal-title":"Circulation"},{"key":"96_CR13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.7326\/0003-4819-133-6-200009190-00009","volume":"133","author":"C Stevinson","year":"2000","unstructured":"Stevinson C, Pittler MH, Ernst E: Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. Ann Intern Med 2000, 133:420\u2013429.","journal-title":"Ann Intern Med"},{"key":"96_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","volume":"69","author":"L Brown","year":"1999","unstructured":"Brown L, Rosner B, Willett WW, et al.: Cholesterollowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999, 69:30\u201342.","journal-title":"Am J Clin Nutr"},{"key":"96_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1067\/mhj.2000.108001","volume":"140","author":"M Michael","year":"2000","unstructured":"Michael M: Current perspectives on the management of hypertriglyceridemia. Am Heart J 2000, 140:232\u2013240.","journal-title":"Am Heart J"},{"key":"96_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJM199701163360301","volume":"336","author":"The Post Coronary Artery Bypass Graft Trial Investigators","year":"1997","unstructured":"The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997, 336:153\u2013162.","journal-title":"N Engl J Med"},{"key":"96_CR17","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1532-5415.1999.tb01568.x","volume":"47","author":"CM Carlsson","year":"1999","unstructured":"Carlsson CM, Carnes M, McBride PE, et al.: Managing dyslipidemia in older adults. J Am Geriatr Soc 1999, 47:1458\u20131465.","journal-title":"J Am Geriatr Soc"},{"key":"96_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229\u2013234. This important paper demonstrated that patients with diabetes without prior infarction had a similar 7-year myocardial infarction risk as nondiabetic patients with previous infarct.","journal-title":"N Engl J Med"},{"key":"96_CR19","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.2337\/diacare.22.1.56","volume":"22","author":"American Diabetes Association","year":"1999","unstructured":"American Diabetes Association: Management of dyslipidemia in adults with diabetes: position statement. Diabetes Care 1999, 22:S56-S59.","journal-title":"Diabetes Care"},{"key":"96_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al., for the AFCAPS\/ TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/ TexCAPS. JAMA 1998, 279:1615\u20131622.","journal-title":"JAMA"},{"key":"96_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(94)90566-5","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383\u20131389.","journal-title":"Lancet"},{"key":"96_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study (WOSCOPS) Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"96_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events (CARE) Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001\u20131009.","journal-title":"N Engl J Med"},{"key":"96_CR24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","unstructured":"The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349\u20131357.","journal-title":"N Engl J Med"},{"key":"96_CR25","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/S0149-2918(00)86740-5","volume":"21","author":"A Cobos","year":"1999","unstructured":"Cobos A, Jovell AJ, Garcia-Altes A, et al.: Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Clin Thera 1999, 21:1924\u20131936.","journal-title":"Clin Thera"},{"key":"96_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199907083410202","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Waters D, Brown WV, et al., for the Atorvastatin versus Revascularization Treatment (AVERT) Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999, 341:70\u201376.","journal-title":"N Engl J Med"},{"key":"96_CR27","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","volume":"160","author":"M Bottorff","year":"2000","unstructured":"Bottorff M, Hansten P: Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 2000, 160:2273\u20132280.","journal-title":"Arch Intern Med"},{"key":"96_CR28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-132-10-200005160-00002","volume":"132","author":"LA Prosser","year":"2000","unstructured":"Prosser LA, Stinnett AA, Goldman PA, et al.: Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000, 132:769\u2013779.","journal-title":"Ann Intern Med"},{"key":"96_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410\u2013418.","journal-title":"N Engl J Med"},{"key":"96_CR30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJM199908123410707","volume":"341","author":"RH Knopp","year":"1999","unstructured":"Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498\u2013511. An in-depth review of the pharmacologic options for treating dyslipidemia.","journal-title":"N Engl J Med"},{"key":"96_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jama.231.4.360","volume":"231","author":"The Coronary Drug Project Research Group","year":"1975","unstructured":"The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360\u2013381.","journal-title":"JAMA"},{"key":"96_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"PL Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long term benefit with niacin. J Am Coll Cardiol 1986, 8:1245\u20131255.","journal-title":"J Am Coll Cardiol"},{"key":"96_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","volume":"82","author":"JR Guyton","year":"1998","unstructured":"Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737\u2013743.","journal-title":"Am J Cardiol"},{"key":"96_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen\/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for the secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605\u2013613.","journal-title":"JAMA"},{"key":"96_CR35","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1056\/NEJM199010043231404","volume":"323","author":"H Buchwald","year":"1990","unstructured":"Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia \u2014report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946\u2013955.","journal-title":"N Engl J Med"},{"key":"96_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","volume":"82","author":"H Mabuchi","year":"1998","unstructured":"Mabuchi H, Koizumi J, Shimizu M, et al.: Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998, 82:1489\u20131495.","journal-title":"Am J Cardiol"},{"key":"96_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","volume":"345","author":"GR Thompson","year":"1995","unstructured":"Thompson GR, Maher V, Matthews S, et al.: Familial hypercholesterolemia regression study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995, 345:811\u2013816.","journal-title":"Lancet"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-001-0096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11936-001-0096-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-001-0096-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-001-0096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T12:28:11Z","timestamp":1652617691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11936-001-0096-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s11936-001-0096-4","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}